These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19903356)

  • 21. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
    Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
    Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
    Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
    Rink L; Skorobogatko Y; Kossenkov AV; Belinsky MG; Pajak T; Heinrich MC; Blanke CD; von Mehren M; Ochs MF; Eisenberg B; Godwin AK
    Mol Cancer Ther; 2009 Aug; 8(8):2172-82. PubMed ID: 19671739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.
    Rikhof B; van der Graaf WT; Suurmeijer AJ; van Doorn J; Meersma GJ; Groenen PJ; Schuuring EM; Meijer C; de Jong S
    Am J Pathol; 2012 Jul; 181(1):303-12. PubMed ID: 22658485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).
    Gupta A; Roy S; Lazar AJ; Wang WL; McAuliffe JC; Reynoso D; McMahon J; Taguchi T; Floris G; Debiec-Rychter M; Schoffski P; Trent JA; Debnath J; Rubin BP
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14333-8. PubMed ID: 20660757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2).
    Cao CL; Niu HJ; Kang SP; Cong CL; Kang SR
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3574-81. PubMed ID: 27649657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
    Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies.
    von Mehren M
    Curr Oncol Rep; 2006 May; 8(3):192-7. PubMed ID: 16618383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.
    Berglund E; Ubhayasekera SJ; Karlsson F; Akcakaya P; Aluthgedara W; Ahlen J; Fröbom R; Nilsson IL; Lui WO; Larsson C; Zedenius J; Bergquist J; Bränström R
    Anticancer Drugs; 2014 Apr; 25(4):415-22. PubMed ID: 24361761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
    Heinrich MC; Corless CL; Blanke CD; Demetri GD; Joensuu H; Roberts PJ; Eisenberg BL; von Mehren M; Fletcher CD; Sandau K; McDougall K; Ou WB; Chen CJ; Fletcher JA
    J Clin Oncol; 2006 Oct; 24(29):4764-74. PubMed ID: 16954519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.
    Prenen H; Guetens G; de Boeck G; Debiec-Rychter M; Manley P; Schoffski P; van Oosterom AT; de Bruijn E
    Pharmacology; 2006; 77(1):11-6. PubMed ID: 16534250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.
    Hsueh YS; Yen CC; Shih NY; Chiang NJ; Li CF; Chen LT
    Autophagy; 2013 Feb; 9(2):220-33. PubMed ID: 23196876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography.
    Prenen H; Deroose C; Vermaelen P; Sciot R; Debiec-Rychter M; Stroobants S; Mortelmans L; Schöffski P; Van Oosterom A
    Anticancer Res; 2006; 26(2A):1247-52. PubMed ID: 16619531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.